E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic or locally recurrent colorectal cancer in genetically unselected patients, followed by recruitment of patients selected for microsatellite positive tumours |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010035 |
E.1.2 | Term | Colorectal cancer stage IV |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010030 |
E.1.2 | Term | Colorectal cancer recurrent |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the anti-tumour activity of EPO906 administered to patients with metastatic or localy recurrent colorectal cancer |
|
E.2.2 | Secondary objectives of the trial |
i. To determine the effect of CIN and MSI on the efficacy of EPO906 as an anticancer agent ii. To describe the safety of EPO906 and quality of life benefits associated with treatment iii. To correlate specific genetic variation with outcome following EPO906 therapy, in particular with reference to APC status (MSI+ APCwt vs MSI APCmutant vs CIN). Other genetic analysis will include but not be limited to, b-catenin, Kras, or Braf mutations; copy number polymorphisms; LOH iv. To retrospectively assess the response to prior treatment in relation to MSI and CIN status, particularly with reference to response to Irinotecan and Oxaliplatin containing regimens
Exploratory objectives To correlate radiological abnormalities at initial presentation with subsequent histopathology, CIN/MSI status, response to treatment, development of metastases, pattern of disease, survival
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histologically confirmed metastatic or locally recurrent carcinoma of the colon or rectum • Prior therapy with oxaliplatin, 5-fluoropyrimidine and irinotecan • Availability of paraffin embedded tumour tissue for analysis of MSI status and CIN • Male or female • 18 years of age or older • Life expectancy of 12 weeks or greater • ECOG performance status 0 or 1 • Clinically and/or radiographically documented measurable disease • Adequate liver function: i. Serum aspartate transaminase (AST) ≤ 5 x upper limit of normal (ULN) ii. Serum alanine transaminase (ALT) ≤ 5 x ULN iii. Serum alkaline phosphatase (ALP) < 5 x ULN iv. Total serum bilirubin < 1.5 x ULN v. Prothrombin time (PT) ≤ 1.5 x ULN • Adequate haematological function: i. Absolute neutrophil count (ANC) ≥1500/µL ii. Platelets ≥100, 000/µL iii. Haemoglobin ≥9.0 g/dL • Serum creatinine clearance of greater than 50ml/min according to the Cockcroft-Gault calculation or measured glomerular filtration rate of >50ml/min • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures • Prior radiotherapy or colostomy are allowed • Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects prior to enrolment • For Cohort B, all patients must have tumours which are MSI positive by IHC
|
|
E.4 | Principal exclusion criteria |
• Persistent toxicity from previous treatment. Neurotoxicity from prior oxaliplatin must have resolved to at least grade 1. • Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell carcinoma of the skin, or adequately treated in-situ cervical cancer • Any of the following within the 12 months prior to study drug administration i. Myocardial infarction or severe/unstable angina, ii. Coronary/peripheral artery bypass graft iii. Symptomatic congestive heart failure iv. Cerebrovascular accident or transient ischemic attack v. Pulmonary embolism • Pregnancy or breastfeeding • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
12 weeks progression free survival in unselected patients |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Trial will finish when all patients have either had progressive CRC, died from metastatic CRC, or survived for 5 years without disease progression. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |